These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37035397)

  • 21. Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.
    Glasser CL; Chen J
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T Cell Subsets During Early Life and Their Implication in the Treatment of Childhood Acute Lymphoblastic Leukemia.
    Saghafian-Hedengren S; Sverremark-Ekström E; Nilsson A
    Front Immunol; 2021; 12():582539. PubMed ID: 33763058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
    August KJ; Narendran A; Neville KA
    Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
    Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
    Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
    JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuing challenges and current issues in acute lymphoblastic leukemia.
    Kansagra A; Dahiya S; Litzow M
    Leuk Lymphoma; 2018 Mar; 59(3):526-541. PubMed ID: 28604239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
    Hucks G; Rheingold SR
    Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.
    Lejman M; Kuśmierczuk K; Bednarz K; Ostapińska K; Zawitkowska J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T cell therapy: A new era for cancer treatment (Review).
    Mohanty R; Chowdhury CR; Arega S; Sen P; Ganguly P; Ganguly N
    Oncol Rep; 2019 Dec; 42(6):2183-2195. PubMed ID: 31578576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
    Ravindranath Y
    Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
    Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects.
    Li W; Zhang Y; Kankala RK; Zou L; Chen Z
    Pharmacology; 2022; 107(7-8):368-375. PubMed ID: 35390793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.